BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cariprazine (Vraylar) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cariprazine (Vraylar)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03817502-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT03817502)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Schizophrenia.\nStudy: Effica
 cy and Safety of Cariprazine in the Treatment of Adolescent Participants (
 13 to 17 Years of Age) With Schizophrenia\nEstimated primary completion: 1
 5 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cari
 prazine-vraylar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03817502
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185815-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cariprazine (Vraylar): Phase 1/2 readout est. (NCT07185815)
DESCRIPTION:Cariprazine (Vraylar)\, phase 1/2\, Major Depressive Disorder.\
 nStudy: Pharmacokinetics\, Safety\, Tolerability and Efficacy of a Subcuta
 neous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects
  Eligible for Treatment With Oral Cariprazine\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cariprazine-vraylar#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185815
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04777357-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT04777357)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Bipolar Disorder.\nStudy: A S
 tudy to Assess Change in Disease Activity and Adverse Events (AEs) With Ca
 riprazine in the Treatment of Depressive Episodes in Pediatric Participant
 s Participants (10 to 17 Years of Age) With Bipolar I Disorder.\nEstimated
  primary completion: March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cariprazine-vraylar#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04777357
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722728-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cariprazine (Vraylar): Phase 2/3 readout est. (NCT07722728)
DESCRIPTION:Cariprazine (Vraylar)\, phase 2/3\, Schizophrenia.\nStudy: A St
 udy to Investigate Pharmacokinetics\, Safety\, and Tolerability of B2227 E
 xtended-Release Injectable Suspension and Vraylar® in Participants With S
 chizophrenia\nEstimated primary completion: August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07722728
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05913947-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Cariprazine (Vraylar): Phase 4 readout est. (NCT05913947)
DESCRIPTION:Cariprazine (Vraylar)\, phase 4\, Bipolar Depression.\nStudy: L
 ithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depressi
 on (DUAG9)\nEstimated primary completion: 1 September 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05913947
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266545-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cariprazine (Vraylar): Phase 4 readout est. (NCT07266545)
DESCRIPTION:Cariprazine (Vraylar)\, phase 4\, Bipolar Depression.\nStudy: R
 NA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipol
 ar Depression (EDIT-ANDRE)\nEstimated primary completion: 31 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cariprazine-vraylar
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 66545
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433635-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Cariprazine (Vraylar): Phase 4 readout est. (NCT06433635)
DESCRIPTION:Cariprazine (Vraylar)\, phase 4\, Bipolar Disorder.\nStudy: Seq
 uential Multiple Assignment Randomized Trial for Bipolar Depression\nEstim
 ated primary completion: 28 February 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06433635
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933538-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Cariprazine (Vraylar): Phase 4 readout est. (NCT05933538)
DESCRIPTION:Cariprazine (Vraylar)\, phase 4\, Major Depressive Disorder.\nS
 tudy: Effectiveness of Cariprazine Monotherapy for Treatment of Major Depr
 essive Disorder\nEstimated primary completion: August 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05933538
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715253-803@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Cariprazine (Vraylar): Phase 1 readout est. (NCT07715253)
DESCRIPTION:Cariprazine (Vraylar)\, phase 1\, Schizophrenia.\nStudy: Longit
 udinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in 
 Schizophrenia\nEstimated primary completion: 30 August 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07715253
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
